Huang Minshan, Chen Hang, Wang Hui, Wang Xianmei, Wang Da, Li Yu, Zhou Qingqing, Zhang Dan, Li Mengwei, Ma Lanqing
The First Affiliated Hospital, Yunnan Institute of Digestive Disease, Kunming Medical University, Kunming, China.
Front Oncol. 2024 Aug 29;14:1424155. doi: 10.3389/fonc.2024.1424155. eCollection 2024.
Metabolic dysfunction-associated steatohepatitis (MASH) is increasingly becoming a prevalent cause of hepatocellular carcinoma (HCC). Our study examines the burden of MASH-related HCC globally, regionally, and nationally, along with associated risk factors from 1990 to 2019, considering variables such as age, sex, and socioeconomic status.
We aimed to report the global, regional, and national burden of liver cancer due to MASH and its attributable risk factors between 1990 and 2019, by age, sex, and sociodemographic index (SDI).
Utilizing the Global Burden of Disease 2019 project, we analyzed data on prevalence, mortality, and disability-adjusted life years (DALYs) for liver cancer attributable to MASH across 204 countries. We provided counts and rates per 100,000 population, including 95% uncertainty intervals.
In 2019, there were 46.8 thousand cases of MASH-related HCC, leading to 34.7 thousand deaths, and 795.8 thousand DALYs globally. While the prevalence increased by 19.8% since 1990, the death and DALY rates decreased by 5.3% and 15.1%, respectively. The highest prevalence was in High-income Asia Pacific, with the greatest increases observed in Australasia, Central Asia, and High-income North America. Southern Sub-Saharan Africa reported the highest death rate, while the lowest rates were in parts of Latin America, Central Sub-Saharan Africa, and Eastern Europe. DALY rates were the highest in Southern Sub-Saharan Africa and the lowest in Tropical Latin America.
The burden of MASH-related HCC is expected to rise slightly over the next decade. This disease, which is not associated with the SDI, remains a major public health problem. In addition, the escalating rates of obesity, demographic shifts, and an aging population could position MASH as a leading factor in liver cancer cases, surpassing viral hepatitis. It is imperative, therefore, that the forthcoming years see the implementation of strategic interventions aimed at the early detection and prevention of liver cancer associated with MASH.
代谢功能障碍相关脂肪性肝炎（MASH）日益成为肝细胞癌（HCC）的常见病因。我们的研究考察了1990年至2019年期间全球、区域和国家层面MASH相关HCC的负担，以及相关风险因素，同时考虑了年龄、性别和社会经济地位等变量。
我们旨在报告1990年至2019年期间，按年龄、性别和社会人口指数（SDI）划分的，由MASH及其可归因风险因素导致的全球、区域和国家层面肝癌负担。
利用全球疾病负担2019项目，我们分析了204个国家中归因于MASH的肝癌的患病率、死亡率和伤残调整生命年（DALY）数据。我们提供了每10万人的病例数和发病率，包括95%的不确定性区间。
2019年，全球有4.68万例MASH相关HCC病例，导致3.47万人死亡，79.58万伤残调整生命年。自1990年以来，患病率上升了19.8%，而死亡率和伤残调整生命年率分别下降了5.3%和15.1%。患病率最高的是高收入亚太地区，其中澳大拉西亚、中亚和高收入北美地区的增幅最大。撒哈拉以南非洲南部的死亡率最高，而拉丁美洲部分地区、撒哈拉以南非洲中部和东欧的死亡率最低。伤残调整生命年率在撒哈拉以南非洲南部最高，在热带拉丁美洲最低。
预计在未来十年，MASH相关HCC的负担将略有上升。这种与社会人口指数无关的疾病仍然是一个主要的公共卫生问题。此外，肥胖率不断上升、人口结构变化和人口老龄化可能使MASH成为肝癌病例的主要因素，超过病毒性肝炎。因此，至关重要的是，在未来几年实施旨在早期发现和预防与MASH相关肝癌的战略干预措施。
